Category Archives: BioUtah News

  Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS). “The management of […]

Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million. The combined, publicly traded company is operating under the name Clene Inc., and its common stock began trading on the NASDAQ Capital Market on […]

Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the CFTR gene. SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) also received approvals to include additional responsive mutations in people with CF ages 6 years and older and age 4 […]

Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform. This new offering follows a fund raise in 2019 of more than $1.1 million via Netcapital.  Proceeds from this latest campaign will further support the development […]

Medsential has announced that it is now offering COVID-19 IgM/IgG rapid antibody tests to point of care providers and is able to meet high demand. The test has recently received FDA emergency use authorization. “We are thrilled to have a point of care rapid antibody test now available. We know hospitals, medical offices, and other […]

ELITech Group recently announced its SARS-CoV-2 Plus Elite MGB Kit received CE marking and has been released. The test kit was developed to distinguish SARS-CoV-2 from other respiratory viruses, including influenza A/B and respiratory syncytial virus types A/B that may have similar symptoms. It runs on the firm’s Elite InGenius platform, as well as other […]